科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ European Journal of Case Reports in Internal Medicine2026-04-20· Medicine

Recurrent pleuropericarditis associated with mesalazine therapy masked by steroid use

Hakan Demiröz, Hasan Eruzun, Handan Doğan Çakmak, Aydın Can Ulusoy, Yusuf Bünyamin Ketenci, Mehmet Akca, Ahmet Bektaş

原始摘要(英文原文)· Original abstract
Introduction: Mesalazine is a cornerstone therapy for ulcerative colitis (UC). Although generally safe, it can cause rare but life-threatening cardiopulmonary complications such as pleuropericarditis. Case description: We report on a patient with a UC flare who presented with dyspnoea, where concurrent pericardial and pleural effusions were detected. The inflammatory response was likely suppressed by concomitant corticosteroid therapy, which masked the clinical manifestations of mesalazine-induced serositis and delayed diagnosis. Two years later, the patient re-presented with recurrent massive pericardial effusion causing tamponade physiology and pleural effusion. Pericardial fluid analysis revealed a haemorrhagic, neutrophil-dominant profile (95% polymorphonuclear leukocyte, mimicking bacterial infection rather than the typically described eosinophilic pattern. Extensive cultures were negative. Following the discontinuation of mesalazine, rapid clinical and radiologic improvement was observed, confirming drug-induced pleuropericarditis. Discussion: This case highlights that mesalazine-associated pleuropericarditis can be obscured by corticosteroids, leading to diagnostic delays. Furthermore, sterile inflammatory reactions to mesalazine can present with atypical neutrophilic features resembling bacterial infection, necessitating a high index of suspicion in inflammatory bowel disease patients presenting with serositis. LEARNING POINTS: A high index of suspicion for drug-induced serositis: in patients with inflammatory bowel disease, pleuropericarditis should be evaluated as a potential side effect of mesalazine rather than assuming it is an extraintestinal manifestation, especially when symptoms recur upon drug re-exposure.Corticosteroids may mask drug toxicity: concomitant corticosteroid therapy can temporarily suppress the clinical symptoms and effusion of mesalazine-induced pleuropericarditis, leading to a 'wrong footing error' and delayed diagnosis once steroids are tapered.Atypical laboratory features: mesalazine-induced sterile inflammatory reactions can present with a neutrophil-dominant effusion profile (rather than the typical eosinophilic pattern), which may mislead the clinician towards an infectious aetiology.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Recurrent pleuropericarditis associated with mesalazine therapy masked by steroid use — 科研速览 Science Skim